Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Axulin is a **plant-based natural health product** formulated as a mixture of botanical extracts, specifically those present in edible herbs and vegetables, identified through screening over 100,000 compounds[1][7][10]. The **active ingredient**—designated as HP-211—targets the IRS-2 branch of the insulin signaling pathway, **enhancing insulin-mediated glucose uptake** into cells and thereby supporting healthy blood sugar metabolism[1][7]. Laboratory and early clinical studies show HP-211 can **increase cellular glucose uptake** and decrease circulating blood glucose and triglyceride levels, with benefits in **insulin resistance, prediabetes, metabolic syndrome, and type II diabetes**[1][4][5][7][10]. Developed after years of research by Housey Pharma, Axulin is marketed as a nutritional support supplement and is **approved by Health Canada as a Natural Health Product** (NPN #80050544)[4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on axulin.